Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.
Istituto Superiore di Sanità , CRIVIB , Viale Regina Elena 299 , I-00161 Roma , Italy.
J Med Chem. 2019 Jan 24;62(2):798-810. doi: 10.1021/acs.jmedchem.8b01482. Epub 2018 Dec 18.
The final stages of polio eradication are proving more difficult than the early phases, and the development of effective drugs and treatments is considered a priority; thus, the research is ongoing. A screening of our in-house chemical library against poliovirus Sabin strains led to the identification of compounds 5 and 6 as hits active at submicromolar concentrations. Derivatives of these compounds were synthesized as a preliminary structure-activity-relationship study. Among them, 7 and 11 were highly active against poliovirus Sabin 1-3. Compound 11 was also very potent against a large panel of wild and vaccine-derived polioviruses. Time-of-addition experiments suggest that 5 and 7 could be active at an early stage of viral replication, whereas 11 was active at same concentration at all stages of viral replication. A ligand-based approach was applied to find the common structural features shared by the new compounds and already-known poliovirus inhibitors.
消灭脊髓灰质炎的最后阶段比早期阶段更为艰难,因此,开发有效的药物和治疗方法被认为是当务之急;目前正在进行相关研究。我们对内部化学文库进行了针对脊髓灰质炎病毒 Sabin 株的筛选,发现化合物 5 和 6 是在亚毫摩尔浓度下具有活性的命中化合物。这些化合物的衍生物被合成作为初步的结构-活性关系研究。其中,化合物 7 和 11 对脊髓灰质炎病毒 Sabin 1-3 具有很高的活性。化合物 11 对大量野生和疫苗衍生的脊髓灰质炎病毒也非常有效。加药时间实验表明,化合物 5 和 7 可能在病毒复制的早期阶段具有活性,而化合物 11 在病毒复制的所有阶段均在相同浓度下具有活性。应用基于配体的方法来寻找新化合物和已知名的脊髓灰质炎病毒抑制剂之间的共同结构特征。